De Novo device
Revi System
Bluewind Medical , Ltd. · Implanted Tibial Electrical Urinary Continence Device (QXM, Class II) · First FDA decision Aug 16, 2023, newest Jul 28, 2026Overactive bladder and urinary incontinence
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
De Novo pathway
Device trials
1
Naming "Revi"
MAUDE reports
30
Brand "Revi", since 2015
PubMed studies
44
Mentioning "Revi"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Revi System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Revi System510(k)
K253651 · Decided Jul 28, 2026 · 250 days after receipt
Device type: Implanted Tibial Electrical Urinary Continence Device (QXM) · GI, Urology & Nephrology
- Revi System510(k)
K252391 · Decided Dec 12, 2025 · 134 days after receipt
Device type: Implanted Tibial Electrical Urinary Continence Device (QXM) · GI, Urology & Nephrology
- Revi System510(k)
K240037 · Decided May 2, 2024 · 118 days after receipt
Device type: Implanted Tibial Electrical Urinary Continence Device (QXM) · GI, Urology & Nephrology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Urine Culture (Bacterial) and Serum Iron Studies (Revision of ICD-9-CM Codes for Pre-operative Examinations)Coding analysisReview closedCAG-00236NUpdated Sep 15, 2026
- Tumor Antigen Immunoassay CA 125 (Revision to Include Additional Personal History of Malignancy Codes)Coding analysisReview closedCAG-00245NUpdated Sep 15, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Swelling of Limb)Coding analysisReview closedCAG-00201NUpdated Sep 15, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Pre-operative Examinations)Coding analysisReview closedCAG-00184NUpdated Sep 15, 2026
- Prothrombin Time and Fecal Occult Blood (Revision of ICD-9-CM Codes for Injury to Gastrointestinal Tract)Coding analysisReview closedCAG-00187NUpdated Sep 15, 2026
- Blood Glucose Testing (Revision of ICD-9-CM Codes for Osteomyelitis)Coding analysisReview closedCAG-00183NUpdated Sep 14, 2026
- Blood Counts (Revision of CPT Codes)Coding analysisReview closedCAG-00182NUpdated Sep 14, 2026
- FDG PET for All Other Cancer Indications Not Previously Specified (Replaced with Section 220.6.17) - RETIREDNational determinationOn the books220.6.15Updated Jun 6, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Revi", any status and sponsor, newest update first.
- RESTORE: An RCT to Evaluate the Efficacy of the Revi SystemPivotal-lookingActive, not recruiting
BlueWind MedicalNot on our public-company list
NCT06217328 · 117 participants · Start Feb 24, 2024 · Primary completion Feb 28, 2026
Device: Revi System Treatment; Revi System - Delayed Activation · For: Urinary Urge Incontinence
Sites: Tucson, Arizona; Pasadena, California; Riverside, California · 19 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Revi", and for the whole product code for context.
This brand
30 reports: 3 malfunction, 27 injury, 0 death
Whole product code QXM
33 reports: 5 malfunction, 27 injury, 0 death
Newest reports for this brand
- REVI SystemInjury
3012239564-2026-00027 · Received Sep 24, 2026 · Event dated Aug 27, 2026
Device type: Implanted Tibial Electrical Urinary Continence Device (QXM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Undesired Nerve Stimulation; Electric Shock
- REVI SystemInjury
3012239564-2026-00026 · Received Aug 6, 2026 · Event dated Jul 9, 2026
Device type: Implanted Tibial Electrical Urinary Continence Device (QXM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Implant Pain
- REVI SYSTEMInjury
3012239564-2026-00025 · Received May 18, 2026 · Event dated May 1, 2026
Device type: Implanted Tibial Electrical Urinary Continence Device (QXM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Post Operative Wound Infection
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Revi"[tiab]. The summary above synthesizes these.
- A Mobile Health App to Support Home-Based Aerobic Exercise in Neuromuscular Diseases: Usability Study.
Veneman T, Koopman FS, Oorschot S, et al. · JMIR Hum Factors · 2024Research Support, Non-U.S. Gov't
- Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study.
Amundsen CL, Sutherland SE, Heesakkers JPFA, et al. · J Urol · 2026Clinical Trial, Multicenter Study
- A gut feeling for drugs that have metabolic benefits.
Zhang E, Agua A, Huang W · Nat Commun · 2023Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Influence of hypersulfated and low molecular weight heparins on ischemia/reperfusion: injury and allograft rejection in rat kidneys.
Gottmann U, Mueller-Falcke A, Schnuelle P, et al. · Transpl Int · 2007Clinical Trial, Research Support, Non-U.S. Gov't
- Radioactive remote signatures derived from Sentinel-2 images and field verification in West Sulawesi, Indonesia.
Saepuloh A, Ratnanta IR, Hede ANH, et al. · Environ Monit Assess · 2023
- Resveratrol intervention attenuates chylomicron secretion via repressing intestinal FXR-induced expression of scavenger receptor SR-B1.
Pang J, Raka F, Heirali AA, et al. · Nat Commun · 2023Research Support, Non-U.S. Gov't
- Rapid functional classification of cardiac genetic variants directly informs precision cardiology.
Wang XT, Chen PT, Mayourian J, et al. · bioRxiv · 2026Preprint
- The Geographical Conditioning of Regional Differentiation Characterising the COVID-19 Pandemic in European Countries.
Mazur M, Baski J, Kamiska W · Int J Environ Res Public Health · 2024
- Cost-utility of implantable tibial neuromodulation (Revi) versus conservative therapy for urgency urinary incontinence in adults: a US payer perspective.
Amundsen CL, Sutherland SE, Lenherr SM, et al. · J Med Econ · 2026
- Systemic medication requirement in post-surgical patients with eosinophilic chronic rhinosinusitis.
Ho J, Li W, Grayson JW, et al. · Rhinology · 2021
- Two-Year Efficacy and Safety Outcomes of the Pivotal OASIS Study Using the Revi System for Treatment of Urgency Urinary Incontinence.
Heesakkers JPFA, Toozs-Hobson P, Sutherland SE, et al. · J Urol · 2025Clinical Trial, Multicenter Study
- Efficacy of the Revi system in treating urgency urinary incontinence.
Masone MC · Nat Rev Urol · 2025Comment
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.